• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of intestinal flora on the antitumor immunity of oncolytic viruses

Research Project

Project/Area Number 19H03434
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 49010:Pathological biochemistry-related
Research InstitutionNagoya University

Principal Investigator

Naoe Yoshinori  名古屋大学, 医学系研究科, 特任准教授 (50392048)

Project Period (FY) 2019-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2021: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2020: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2019: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Keywords腫瘍溶解性ウイルス / C-REV / 腸内細菌叢 / 抗生物質 / 抗腫瘍効果 / 免疫 / 癌
Outline of Research at the Start

腫瘍溶解性ウイルスは腫瘍特異的に感染し、腫瘍を崩壊する。さらに、破壊された腫瘍が癌抗原を放出することにより癌免疫応答を惹起する。一方、腸内菌叢は腸管局所のみならず、全身的な免疫にも大きな影響を与えていることが明らかになりつつある。これらのことから、腫瘍溶解性ウイルスの効果に腸内細菌叢が影響することは容易に考えられるが、詳細な報告は全くない。本研究では、腸内細菌叢の変化による免疫反応の変化が、腫瘍溶解性ウイルスが惹起する癌免疫応答反応にどのように影響を与え、抗腫瘍効果をいかに調節するかを明らかにすることを目的に行う。

Outline of Final Research Achievements

Changes in the intestinal flora were observed by administration of C-REV to antibiotic-treated mice in the intraperitoneal transplant model and the subcutaneous transplant model. The antitumor effect of C-REV changes depending on the combination of the four antibiotics Ampicillin (A), Metronidazole (M), Neomycin (N), or Vancomycin (V), and the order of the effect is (large effect) AMNV = AMV > MNV > ANV = AMN (small effect). The difference in the bacterial flora of the mice by the antibiotic cocktail treatment was found, and a large change was observed in the bacterial flora with and without the antibiotic cocktail treatment.

Academic Significance and Societal Importance of the Research Achievements

腸内細菌叢の変化により化学療法、免疫チェックポイント阻害剤の抗腫瘍効果が変化することが報告されているが、腫瘍溶解性ウイルスの抗腫瘍効果が変化するかは不明であった。今回の研究結果から抗生剤処理により腫瘍溶解性ウイルスの抗腫瘍効果が変化することを見出し、その抗腫瘍効果の変化に腸内細菌叢が関与する結果を得た。

Report

(4 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Annual Research Report
  • 2019 Annual Research Report
  • Research Products

    (17 results)

All 2021 2019 Other

All Journal Article (4 results) (of which Peer Reviewed: 4 results,  Open Access: 2 results) Presentation (10 results) (of which Int'l Joint Research: 2 results,  Invited: 1 results) Remarks (1 results) Patent(Industrial Property Rights) (2 results) (of which Overseas: 2 results)

  • [Journal Article] C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells2021

    • Author(s)
      Daishi Morimoto, Shigeru Matsumura, Itzel Bustos-Villalobos, Patricia Angela Sibal, Toru Ichinose, Yoshinori Naoe, Ibrahim Ragab Eissa, ohamed Abdelmoneim, Nobuaki Mukoyama, Noriyuki Miyajima, Maki Tanaka, Yasuhiro Kodera and Hideki Kasuya
    • Journal Title

      Cells

      Volume: 10 Issue: 6 Pages: 1-16

    • DOI

      10.3390/cells10061502

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Oncolytic herpes simplex virus HF10 (canerpaturev, C-REV) promotes accumulation of CD8+PD-1- tumor-infiltrating T cells in PD-L1 enriched tumor microenvironment.2021

    • Author(s)
      Eissa I.R., Mukoyama N., Abdelmoneim, M., Naoe, Y., Matsumura, S., Bustos-Villalobos I., Ichinose T., Miyajima N., Morimoto D., Tanaka M., Fujimoto, Y., Kodera Y., Kasuya H.
    • Journal Title

      Int. J. Cancer

      Volume: 1 Issue: 1 Pages: 1-14

    • DOI

      10.1002/ijc.33550

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model2021

    • Author(s)
      Noriyuki Miyajima, Ibrahim Ragab Eissa, Mohamed Abdelmoneim, Yoshinori Naoe, Toru Ichinose, Shigeru Matsumura, Itzel Bustos-Villalobos, Nobuaki Mukoyama, Daishi Morimoto, Masahiro Shibata, Dai Takeuchi, Nobuyuki Tsunoda, Toyone Kikumori, Maki Tanaka, Yasuhiro Kodera, Hideki Kasuya
    • Journal Title

      Nagoya J Med Sci .

      Volume: 83 Pages: 683-696

    • NAID

      120007174359

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth2019

    • Author(s)
      Wu Zhiwen、Ichinose Toru、Naoe Yoshinori、Matsumura Shigeru、Villalobos Itzel Bustos、Eissa Ibrahim Ragab、Yamada Suguru、Miyajima Noriyuki、Morimoto Daishi、Mukoyama Nobuaki、Nishikawa Yoko、Koide Yusuke、Kodera Yasuhiro、Tanaka Maki、Kasuya Hideki
    • Journal Title

      Molecular Therapy - Oncolytics

      Volume: 13 Pages: 107-115

    • DOI

      10.1016/j.omto.2019.04.004

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] 腫瘍溶解性ウイルスC-REV(HF10)に関連する抗腫瘍因子の検討2019

    • Author(s)
      Hideki Kasuya, Daishi Morimoto, Yoshinori Naoe, Shigeru Matsumura, Itzel Bustos, Ibrahim Eissa, Maki Tanaka
    • Organizer
      第21回外科分子細胞治療研究会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 腫瘍溶解性ウイルスC-REV(旧 HF10)による膵癌延命治療の可能性2019

    • Author(s)
      Hideki Kasuya, Yoshiki Hirooka, Maki Tanaka
    • Organizer
      第105回日本消化器病学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 腫瘍溶解性ウイルスC-REVの膵臓癌に対する効果関連因子の探索2019

    • Author(s)
      Hideki Kasuya, Yoshiki Hirooka, Yoshinori Naoe, Shigeru Matsumura, Daishi Morimoto, Ibrahim Eissa, Maki Tanaka
    • Organizer
      第50回日本膵臓学会大会
    • Related Report
      2019 Annual Research Report
  • [Presentation] PD-L1 Blockade Enhanced the Therapeutic Efficacy of the Oncolytic Virus-Canerpaturev in Squamous Carcinoma2019

    • Author(s)
      Ibrahim Eissa, Nobuaki Mukoyama, Yoshinori Naoe, Shigeru Matsumura, Toru Ichinose, Itzel Bustos, Daishi Morimoto, Noriyuki Miyajima, Maki Tanaka, Hideki Kasuya
    • Organizer
      第25回日本遺伝子細胞治療学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Combination therapy of Cetuximab and CANERPATUREV suppresses human colorectal cancer growth2019

    • Author(s)
      Shigeru Matsumura, Zhiwen Wu, Toru Ichinose, Yoshinori Naoe, Itzel Bustos, Ibrahim Eissa, Suguru Yamada, Noriyuki Miyajima, Daishi Morimoto Nobuaki Mukoyama Yoko Nishikawa, Yusuke Koide, Yasuhiro Kodera, Maki Tanaka, Hideki Kasuya
    • Organizer
      第25回日本遺伝子細胞治療学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Antitumor factors associated with oncolytic virus C-REV(formaly HF10)2019

    • Author(s)
      Hideki Kasuya, Yoshiki Hirooka, Masaya Suenaga, Daishi Morimoto, Yoshinori Naoe, Shigeru Matsumura, Maki Tanaka
    • Organizer
      The 17th IDDST conference
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] PD-L1 Blockade Enhanced the Therapeutic Efficacy of Oncolytic Virus Canerpaturev in Squamous Cell Carcinoma Model2019

    • Author(s)
      Ibrahim Eissa, Nobuaki Mukoyama, Yoshinori Naoe, Shigeru Matsumura, Toru Ichinose, Itzel Bustos, Daishi Morimoto, Noriyuki Miyajima, Maki Tanaka, Hideki Kasuya
    • Organizer
      第23回日本がん免疫学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Combination of Cetuximab and oncolytic virus CANERPATUREV synergistically inhibits human colorectal cancer growth2019

    • Author(s)
      Shigeru Matsumura, Zhiwen Wu, Toru Ichinose, Yoshinori Naoe, Itzel Bustos, Ibrahim Eissa, Suguru Yamada, Yasuhiro Kodera, Maki Tanaka, Hideki Kasuya
    • Organizer
      第23回日本がん免疫学会総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Combination of Cetuximab and oncolytic virus CANERPATUREV synergistically inhibits human colorectal cancer growth2019

    • Author(s)
      Shigeru Matsumura, Zhiwen Wu, Toru Ichinose, Ibrahim Eissa, Yoshinori Naoe, Yasuhiro Kodera, Maki Tanaka, Hideki Kasuya
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Clinical development of Canerpaturev(formerly HF10)as the novel cancer therapy2019

    • Author(s)
      Hideki Kasuya, Yoshinori Naoe, Shigeru Matsumura, Maki Tanaka
    • Organizer
      The 12th International Oncolytic Virotherapy Conference
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Remarks] 名古屋大学大学院医学系研究科 癌免疫治療研究室

    • URL

      https://www.med.nagoya-u.ac.jp/intlexch/cancerimmuno/www/index.html

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report 2019 Annual Research Report
  • [Patent(Industrial Property Rights)] 1型単純ヘルペスウイルス2021

    • Inventor(s)
      直江吉則
    • Industrial Property Rights Holder
      名古屋大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2020-051489
    • Filing Date
      2021
    • Related Report
      2021 Annual Research Report
    • Overseas
  • [Patent(Industrial Property Rights)] キメラ標的因子受容体2021

    • Inventor(s)
      直江吉則
    • Industrial Property Rights Holder
      名古屋大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-005337
    • Filing Date
      2021
    • Related Report
      2021 Annual Research Report
    • Overseas

URL: 

Published: 2019-04-18   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi